| 000 | 01418 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250516065305.0 | ||
| 264 | 0 | _c20120605 | |
| 008 | 201206s 0 0 eng d | ||
| 022 | _a0015-5500 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMikusová, V | |
| 245 | 0 | 0 |
_aMitoxantrone in combination with a DNA-PK inhibitor: possible therapy of promyelocytic leukaemia resistant forms. _h[electronic resource] |
| 260 |
_bFolia biologica _c2011 |
||
| 300 |
_a200-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAcid Anhydride Hydrolases |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 |
_aCell Cycle Proteins _xgenetics |
| 650 | 0 | 4 | _aDNA Breaks, Double-Stranded |
| 650 | 0 | 4 | _aDNA End-Joining Repair |
| 650 | 0 | 4 |
_aDNA Repair Enzymes _xgenetics |
| 650 | 0 | 4 |
_aDNA-Activated Protein Kinase _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aDNA-Binding Proteins _xgenetics |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 |
_aHL-60 Cells _xdrug effects |
| 650 | 0 | 4 | _aHomologous Recombination |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Promyelocytic, Acute _xdrug therapy |
| 650 | 0 | 4 |
_aMitoxantrone _xpharmacology |
| 650 | 0 | 4 |
_aNuclear Proteins _xgenetics |
| 700 | 1 | _aTichý, A | |
| 700 | 1 | _aRezáčová, M | |
| 700 | 1 | _aVávrová, J | |
| 773 | 0 |
_tFolia biologica _gvol. 57 _gno. 5 _gp. 200-5 |
|
| 999 |
_c21349499 _d21349499 |
||